David Potter to Ocular Hypertension
This is a "connection" page, showing publications David Potter has written about Ocular Hypertension.
Connection Strength
0.617
-
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. J Ocul Pharmacol Ther. 2002 Dec; 18(6):507-14.
Score: 0.197
-
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. Exp Eye Res. 1999 Aug; 69(2):227-38.
Score: 0.156
-
Centrally mediated ocular hypotension: potential role of imidazoline receptors. Ann N Y Acad Sci. 1995 Jul 12; 763:463-85.
Score: 0.118
-
Ocular hypertensive response to beta-adrenoceptor agonists. Curr Eye Res. 1982-1983; 2(10):711-9.
Score: 0.046
-
Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine. J Pharmacol Exp Ther. 1993 Nov; 267(2):822-7.
Score: 0.026
-
Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits. J Ocul Pharmacol. 1993; 9(3):187-99.
Score: 0.025
-
LY141865: a relatively selective DA2 agonist with complex ocular activity. J Ocul Pharmacol. 1988; 4(1):19-28.
Score: 0.017
-
Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function. J Ocul Pharmacol. 1987; 3(4):309-21.
Score: 0.016
-
Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Curr Eye Res. 1986 Sep; 5(9):665-76.
Score: 0.016